SIRT5 and ovarian carcinoma: SIRT5 is overexpressed in ovarian cancer tissues and promotes cisplatin resistance in ovarian cancer cells by inhibiting cisplatin-induced ROS-dependent DNA damage by regulating the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway (56).